ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City.
Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia … ImmunoPrecise is an 'end-to-end' provider for accelerated antibody research and discovery.
Price: 0.63 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...
FOR OUR FULL DISCLAIMER CLICK HERE
CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the first patient of a new Phase 1b/2 clinical trial for its metastatic triple-negative breast cancer treatment leronlimab reported encouraging initial results. Pourhassan says the Vancouver, Washington-based biotechnology...
Director Interviews
Full interview: Matinas BioPharma CMO says upcoming Amarin FDA...
Basic Materials
Retail & consumer
Health
Industry & services
Industry & services
Prev article
